A Clinical Study of TQH2929 in Healthy Adult Subjects

Study Purpose

This project is divided into a single dose escalation and a multiple dose escalation phase Ia clinical study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929 injection in healthy adults.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 55 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Adults aged between 18 and 55 years old (inclusive), both male and female; - The male subject should weigh at least 50 kg, the female subject should weigh at least 45kg.
And body mass index (BMI) within 19~26 kg/m2.
  • - Good health is defined as having no clinically relevant abnormalities identified by a detailed medical history, clinical signs, vital signs, full physical examination, 12-lead Electrocardiogram (ECG), Chest radiograph, abdominal ultrasound and clinical laboratory tests.
  • - Subjects voluntarily joined the study, sign informed consent form before the study and fully understand the study content.
  • - Have no pregnancy plan and voluntarily take effective contraception measures from time of screening to at least 6 months after the last dose (subjects and their partners).

Exclusion Criteria:

  • - Pregnant or lactating women; - Past medical history or current cardiac, endocrine, metabolic, renal, hepatic, gastrointestinal, skin, infection, hematological, neurological or psychiatric diseases/abnormalities, or related chronic abnormalities, or related chronic diseases, or acute diseases, and evaluated the investigator to be not suitable for the trial; - People who have abnormal and clinically significant results in vital signs, physical examination, laboratory tests, 12-lead ECG, Chest radiograph and abdominal ultrasound during screening period; - Subjects positive for any of Hepatitis B Virus Surface Antigen (HBsAg), Hepatitis C Virus Antibody (Anti-HCV), Human Immunodeficiency Virus Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP) tests; - Subjects positive for tuberculoses spot (T-SPOT) result; - Clinically significant infection requiring antibiotic or antiviral therapy prior to screening and the entire study period; - Had undergone surgery within 4 weeks prior to screening period or expected to undergo surgery during the study period; - Participated in any clinical trial within 3 months prior to the screening period; - Received immunoglobulins or blood products within 30 days prior to randomization; - Blood donation or significant blood loss of more than 400 mL within 2 months prior to randomization; - People who have potential difficulty in blood collection, or have a history of needles or blood sickness; - Any clear history of drug or food allergies, particularly those with allergies to similar components to the investigational drugs in this trial; - People who have received or are planning to receive inactivated or active vaccines during the 30 days prior to randomization and the entire study period (including the follow-up period); - Smoking more than 5 cigarettes per day or using equivalent amounts of nicotine or nicotine-containing products within 6 months prior to randomization, or those who cannot stop using any tobacco-based products during the trial; - People who had long-standing alcohol abuse or alcohol consumption of more than 14 units (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of wine) of alcohol per week within 3 months prior to screening, or those who cannot refrain from alcohol during the trial, or those who tested positive for alcohol breath; - History of drug abuse or a positive result of urine drug test at screening; - Received any marketed or investigational biologics within 4 months or 5 half-lives (whichever is longer) prior to randomization; - Had taken any prescription drugs, over-the-counter drugs, or herbs within 4 weeks prior to randomization, with the exception of vitamin products; - Use of any systemic cytotoxicity or systemic immunosuppressants within 6 months prior to randomization or during the study period, or any local cytotoxin or local immunosuppressive drug within 30 days or 5 half-life periods (whichever is longer) prior to randomization or during the study period; - Any situation in which the investigator believes that this poses a safety risk to the subject in the trial or may interfere with the conduct of the study, or that the investigator believes that the subject may not be able to complete the study or may not be able to comply with the requirements of the study.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries China

The disease, disorder, syndrome, illness, or injury that is being studied.

Arms & Interventions


Experimental: TQH2929 Injection (1 mg/kg)

TQH2929 Injection 1 mg/kg is administered as a single dose.

Experimental: TQH2929 Injection (3 mg/kg)

TQH2929 Injection 3 mg/kg is administered as a single dose.

Experimental: TQH2929 Injection (10 mg/kg)

TQH2929 Injection 10 mg/kg is administered as a single dose.

Experimental: TQH2929 Injection (20 mg/kg)

TQH2929 Injection 20 mg/kg is administered as a single dose.

Experimental: TQH2929 Injection (30 mg/kg)

TQH2929 Injection 30 mg/kg is administered as a single dose.

Experimental: TQH2929 Injection (40 mg/kg)

TQH2929 Injection 40 mg/kg is administered as a single dose.

Placebo Comparator: Placebo Injection

Placebo injection is administered as a single dose or multiple doses (once every two weeks).

Experimental: TQH2929 Injection (900 mg)

TQH2929 Injection 900 mg is administered once every two weeks.

Experimental: TQH2929 Injection (1500 mg)

TQH2929 Injection 1500 mg is administered once every two weeks.

Experimental: TQH2929 Injection (1800 mg)

TQH2929 Injection 1800 mg is administered once every two weeks.


Drug: - TQH2929 injection

TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.

Drug: - Placebo injection

Placebo comparator

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Peking University First Hospital, Beijing, Beijing, China




Peking University First Hospital

Beijing, Beijing, 100871

Site Contact

Xia Zhao, Master



The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.